Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes coronavirus disease 2019 (COVID-19), which manifests with pulmonary symptoms that show up as diffuse alveolar damage (DAD), pneumocyte hyperplasia and proliferation, excess inflammation, and platelet aggregate or thromboemboli formation in histological studies. The mechanisms behind these histological findings are still unclear. Previous studies published on PubMed
Clinical Trials & Research
Print this page PLYMOUTH MEETING, Pa., Sept. 28, 2020 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that the U.S. Food and Drug Administration (FDA) has notified the company it has additional questions about the company’s
Nine months into the coronavirus pandemic, the global case toll has now topped 33 million, with over one million deaths. As the global health crisis continues to wreak havoc, scientists are finding more links between underlying medical conditions and severe coronavirus disease (COVID-19). A team of researchers at the Universitas Indonesia in Jakarta, Indonesia, has
Print this page GAITHERSBURG, Md., Sept. 24, 2020 (GLOBE NEWSWIRE) – Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has initiated its first Phase 3 study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. The trial is being conducted in the United Kingdom (UK),
Reviewed by Emily Henderson, B.Sc.Sep 26 2020 A novel mobile health program created in early 2018 by the Kraft Center for Community Health at Massachusetts General Hospital (MGH) has proven to be an effective model for bringing opioid addiction treatment services directly to marginalized individuals, particularly the homeless, a population that faces the highest risk
Print this page TOKYO — September 23, 2020 FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada; hereinafter “FUJIFILM Toyama Chemical”) has announced today that primary endpoint has been met in phase III clinical trial of “Avigan Tablet” (generic name: favipiravir, “Avigan”) conducted in Japan for patients with novel coronavirus infections (hereinafter “COVID-19”). The efficacy primary
Reviewed by Emily Henderson, B.Sc.Sep 24 2020 Researchers have identified two antibodies that protect mice against lethal infections of influenza B virus, report scientists at Washington University School of Medicine in St. Louis and Icahn School of Medicine at Mount Sinai. Together with an antibody that targets the other major kind of influenza viruses that
Print this page NEW BRUNSWICK, N.J., September 23, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a
Even as the world is reeling under the COVID-19 pandemic and the unprecedented toll it has taken in terms of deaths, long-term health conditions, and economic turmoil, scientists from all over the world are frantically trying to find an effective way to control the spread of disease and treat those who are already affected. Many
Print this page Tokyo, Basking Ridge, N.J. and Munich – (September 14, 2020) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the first patient has been dosed in a phase 2 study evaluating patritumab deruxtecan (U3-1402), a HER3 directed DXd antibody drug conjugate (ADC), in patients with advanced or metastatic colorectal cancer who
The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected over 30 million individuals worldwide. Originating in Wuhan (China) at the end of 2019, the virus and has claimed over 959,000 lives to date. While most patients present with fever, cough, and fatigue, some progress to acute respiratory distress syndrome or
Print this page INDIANAPOLIS, Sept. 14, 2020 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). ACTT-2 included more than 1,000 patients and began
Modeling indicates that secondary structures of RNA in the genes encoding the Nsp4 and Nsp16 proteins of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are different from other related coronavirus species, and this may affect some viral molecular processes. With the dramatic spread of COVID-19 caused by the SARS-CoV-2 coronavirus, there has been a
Print this page INDIANAPOLIS, Sept. 16, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced proof of concept data from an interim analysis of the BLAZE-1 clinical trial, showing a reduced rate of hospitalization for patients treated with LY-CoV555. The randomized, double-blind, placebo-controlled Phase 2 study evaluated LY-CoV555, a SARS-CoV-2 neutralizing antibody, for the treatment
Reviewed by Emily Henderson, B.Sc.Sep 16 2020 Scientists at St. Jude Children’s Research Hospital have identified the structure of double-strand DNA break repair by PARP enzymes. The findings show that PARP2 can bridge the gap, bringing two broken DNA ends together. The study also provides insight into the mechanisms that underlie PARP activation and the
Print this page HAMILTON, Bermuda, Sept. 15, 2020 (GLOBE NEWSWIRE) – Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to mavrilimumab for the treatment of giant cell arteritis (GCA). Mavrilimumab
Reviewed by Emily Henderson, B.Sc.Sep 14 2020 The Food and Drug Administration is weighing whether to follow British regulators in resuming a coronavirus vaccine trial that was halted when a participant suffered spinal cord damage, even as the National Institutes of Health has launched an investigation of the case. “The highest levels of NIH are
Print this page London, UK and Paris, France 03 September 2020 — Sanofi and GSK announce today the start of the Phase 1/2 clinical trial for their adjuvanted COVID-19 vaccine. The vaccine candidate, developed in partnership by Sanofi and GSK, uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s
Reviewed by Emily Henderson, B.Sc.Sep 12 2020 Dipanjan Pan, professor of chemical, biochemical, and environmental engineering at UMBC, and collaborators published a seminal study in Nature Communications that demonstrates for the first time a method of biosynthesizing plasmonic gold nanoparticles within cancer cells, without the need for conventional bench-top lab methods. It has the potential
Print this page 09 September 2020 — As part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus vaccine, AZD1222, a standard review process has been triggered, leading to the voluntary pause of vaccination across all trials to allow an independent committee to review the safety data of a single event of an unexplained
Reviewed by Emily Henderson, B.Sc.Sep 10 2020 FINDINGS A new study by researchers at the UCLA Jonsson Comprehensive Cancer Center sheds light on how interferon-gamma (IFN-y), an immune response-stimulating signaling molecule that helps activate immune cells, guides the treatment response in people with advanced melanoma who are treated with one of the leading immunotherapies -;
Print this page KENILWORTH, N.J.–(BUSINESS WIRE) September 8, 2020 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced the results from two pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant (MK-7264), an investigational, orally administered, selective P2X3 receptor antagonist, for the potential treatment